Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Sulfasalazine has long been used for the treatment of rheumatoid arthritis and is often chosen as a first-line treatment. Here, we report a case of sulfasalazine-induced autoimmune thrombocytopenia and review the mechanisms behind drug-induced immune thrombocytopenia (DITP) and the approach to its diagnosis and management.

Original publication

DOI

10.1007/s10067-016-3420-9

Type

Journal article

Journal

Clin rheumatol

Publication Date

02/2017

Volume

36

Pages

477 - 479

Keywords

Autoantibodies, Blood platelets disorders, Hematologic diseases, Rheumatic diseases, Rheumatoid arthritis (RA), Thrombocytopenia, Tissues or models, Aged, Arthritis, Rheumatoid, Blood Platelets, Humans, Male, Purpura, Thrombocytopenic, Idiopathic, Remission Induction, Sulfasalazine, Treatment Outcome